CLINICAL PATHOLOGY EVALUATION OF MONKEY SERUM

This notice is a combined synopsis/solicitation for commercial items using Simplified Acquisition Procedures. This acquisition will be made in accordance with the format in Federal Acquisition Regulation (FAR) Subpart 12.6 "Streamlined Procedures for Evaluation and solicitation for commercial Items," as applicable, and as supplemented with additional information included in this notice. This announcement constitutes the only solicitation (a written solicitation will not be issued) and quotes are being requested. The Solicitation number is RFQ-NIAID-2085819 and the solicitation is issued as a Request for Quotes (RFQ). This acquisition will be processed under FAR Part 13 Simplified Acquisition Procedures (SAP). The solicitation documents and incorporated provisions and clauses are those in effect through Federal Acquisition Circular (FAC) 2021-05 March 10, 2021. The North American Industry Classification System (NAICS) code for this procurement is 541380, Testing Laboratory, with a small business size standard of $16.5M. The requirement is being competed full and open competition, un-restricted and without a small business set-aside. The Vaccine Research Center (VRC) is part of the National Institute of Allergy and Infectious Diseases (NIAID) who develops vaccines against human immunodeficiency virus (HIV). The VRC conducts research that facilitates the development of effective vaccines. Towards this end, the goal has been to develop vaccine immunogens that elicit antibodies against various targets, along with further optimization through iterations of this procedure. One of the programs the VRC is developing is the vaccine to reduce blood cholesterol levels. To achieve this goal, blood cholesterol levels need to be evaluated throughout in a number of our studies. A vendor with proven capability providing high quality clinical pathology evaluation of blood cholesterol levels is critical to the success of the program. The service the lab is procuring is the "Clinical Pathology Evaluation of Monkey Serum" for 400 NHP serum samples. The following parameters will be evaluated: cholesterol, non-esterified fatty acids, HDL, LDL, and triglycerides. Remaining samples will be stored per CRL SOP and discarded after analysis. A report of data tables provided to VRC after analysis. There were 30 assays completed in December 2020 and 130 assays completed in June 2021, it was determined that CRL is capable of meeting the needs and providing the assays and data. Due to the data received in the previous study, this study will provide 400 samples to be sent over the next 4 months that required the assay from the same vendor for historical comparison. Other vendors that provide the service perform and validate the assay differently which can lead to variable data. Place of Performance: NIH, 9000 Rockville Pike, Bethesda, MD 20892 The government intends to award a firm fixed price purchase order to the responsible contractor as a result of this RFQ that will include the terms and conditions set forth herein. The award will be based on the lowest price technically acceptable. The technical capability to meet the above requirements and price. The following FAR provisions apply to this acquisition: FAR 52.212-1 Instructions to Offerors Commercial Items (June 2020) FAR 52.212-3 Offerors Representations and Certifications - Commercial Items (FEB 2021) FAR 52.204-7 System for Award Management (Oct 2018) (Offerors must complete annual representations and certifications on-line at http://www.sam.gov/ in accordance with FAR 52.212-3 Offerors Representations and Certifications- Commercial Items (Please ensure 52.209-2 -- Prohibition on Contracting with Inverted Domestic Corporations--Representation. (Nov 2015) is updated in your SAM record) FAR 52.203-18 Prohibition on Contracting with Entities that Require Certain Internal Confidentiality Agreements - Representation (Jan 2017) 52.204'26 Covered Telecommunications Equipment or Services-Representation (OCT 2020) *** Must complete representation if attached to this solicitation- see attachment 52.204-26 The following FAR contract clauses apply to this acquisition: FAR 52-212-4 Contract Terms and Conditions Commercial Items (OCT 2018) FAR 52-212.5 Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items (JUL 2021) *The applicable subparagraphs of FAR52.212-5 are included in the attachment to this posting. FAR 52.232-40 Providing Accelerated Payments to Small Business Subcontractors (Dec 2013) FAR 52.204-13 System for Award Management Maintenance (Oct 2018) FAR 52.204-25 Prohibition on Contracting for Certain Telecommunications and Video Surveillance Services or Equipment (Aug 2020) HHSAR 352.222-70, Contractor Cooperation in Equal Employment Opportunity Investigations (December 2015) 52.252-2 -- Clauses Incorporated by Reference. (Feb 1998) This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this address: http://farsite.hill.af.mil/vffara.htm By submission of an offer, the offeror acknowledges the requirement that a prospective awardee shall be registered in the System for Award Management (SAM) database prior to award, during performance, and through final payment of any contract, basic agreement, basic ordering agreement, or blanket purchasing agreement resulting from this solicitation (www.sam.gov). Copies of the above-referenced provisions and clauses are available from http://www.acquisition.gov/far/loadmainre.html & http: //www.hhs.gov/regulation/index.html or, upon request, either by telephone or fax. Submission shall be received not later than August 30, 2021 @ 12:00 PM EST Offers may be e-mailed to Maliaka Pinkney at (contact@example.gov). Offers shall include RFQ number in the subject line (RFQ-NIAID-2085819). Late submissions shall be treated in accordance with the solicitation provision at FAR 52.212-1(f) All responsible sources may submit an offer that will be considered by this Agency. Any questions or concerns regarding this solicitation should be forwarded in writing via e-mail to Maliaka Pinkney at contact@example.gov.